[The role of SGLT-2 inhibitors in the treatment of type 2 diabetes]

MMW Fortschr Med. 2015 Jan 19;157(1):55-8. doi: 10.1007/s15006-015-2590-8.
[Article in German]
No abstract available

Publication types

  • Review

MeSH terms

  • Benzhydryl Compounds / therapeutic use
  • Canagliflozin
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Drug Therapy, Combination
  • Glucosides / therapeutic use
  • Glycated Hemoglobin / metabolism
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Metformin / therapeutic use
  • Sodium-Glucose Transporter 2
  • Sodium-Glucose Transporter 2 Inhibitors*
  • Thiophenes / therapeutic use

Substances

  • Benzhydryl Compounds
  • Glucosides
  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • SLC5A2 protein, human
  • Sodium-Glucose Transporter 2
  • Sodium-Glucose Transporter 2 Inhibitors
  • Thiophenes
  • hemoglobin A1c protein, human
  • Canagliflozin
  • dapagliflozin
  • Metformin
  • empagliflozin